Schedule 13G ownership disclosure

HELIX ACQUISITION CORP II

Class A Ordinary Shares, par value $0.0001 per share · CUSIP: G4444H101

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Integrated Core Strategies (US) LLC

    Shares: 833,125.00 · Class: 4.4%

  • Millennium Management LLC

    Shares: 897,251.00 · Class: 4.7%

  • Millennium Group Management LLC

    Shares: 897,251.00 · Class: 4.7%

  • Israel A. Englander

    Shares: 897,251.00 · Class: 4.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-072172
Form type
SCHEDULE 13G/A
Filer
BridgeBio Oncology Therapeutics, Inc.
CIK
CIK 1869105
Filed
Jul 30, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub